Ascendis Pharma A/S (NASDAQ: ASND) is one of 297 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Ascendis Pharma A/S to similar businesses based on the strength of its profitability, institutional ownership, dividends, valuation, earnings, analyst recommendations and risk.
This is a breakdown of recent ratings and target prices for Ascendis Pharma A/S and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Ascendis Pharma A/S||0||1||5||0||2.83|
|Ascendis Pharma A/S Competitors||792||3133||11394||228||2.71|
Ascendis Pharma A/S presently has a consensus target price of $36.95, suggesting a potential upside of 3.97%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.06%. Given Ascendis Pharma A/S’s rivals higher possible upside, analysts plainly believe Ascendis Pharma A/S has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Ascendis Pharma A/S and its rivals revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Ascendis Pharma A/S||$5.10 million||-$75.80 million||-10.24|
|Ascendis Pharma A/S Competitors||$290.00 million||$35.57 million||149.94|
Ascendis Pharma A/S’s rivals have higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Ascendis Pharma A/S and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Ascendis Pharma A/S||-2,977.70%||-67.76%||-60.93%|
|Ascendis Pharma A/S Competitors||-5,117.95%||-418.31%||-40.70%|
Institutional & Insider Ownership
65.0% of Ascendis Pharma A/S shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.5% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Ascendis Pharma A/S rivals beat Ascendis Pharma A/S on 6 of the 11 factors compared.
Ascendis Pharma A/S Company Profile
Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.